Support to get you started on IDELVION

Questions to consider when talking to your doctor about IDELVION

Interested in IDELVION? Wondering about the benefits of fewer infusions? Download the Doctor Discussion Guide below to have a constructive conversation with your doctor.

Print the guide

Financial assistance to provide access to IDELVION

My Source logo

Everybody's financial situation is unique. In the sections below, you'll find answers to the following questions.

Expand All

Questions about insurance?

Navigating the health insurance reimbursement process and beyond can be confusing to even the most experienced individual.

We're here to help. Call 1-800-676-4266 to speak with an IDELVION MySourceSM Care Coordinator who can answer questions about insurance, get information you may need, and refer you to programs you may be eligible for.

Experiencing a lapse in coverage?

Life changes happen. The CSL Behring AssuranceSM program can help people who rely on IDELVION to continue to receive treatment if a lapse in coverage occurs.

Patients on therapy earn points for every month of continuous IDELVION use. These points are redeemable for IDELVION therapy in the event of insurance coverage loss. Points are issued based on product use from the date that enrollment eligibility is approved, so it's important to enroll as soon as possible.

To enroll, simply call 1-800-676-4266 to speak with an IDELVION MySourceSM Care Coordinator today.

Underinsured or uninsured?

If you do not have insurance or cannot afford your treatment, our Patient Assistance Program may be able to help. The goal of the program is to ensure that individuals in these circumstances have access to their therapy.

For more information, speak with an IDELVION MySourceSM Care Coordinator at 1-800-676-4266.

Zero bleeds

IDELVION delivers a median annualized spontaneous bleeding rate of zero in clinical trials*

See IDELVION powerful protection
Sign up for IDELVION icon

Is it time for a Factor IX switch? Get the information you need

Sign up here

*Zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials.

You are now leaving the current website.

Do you want to continue?

No Yes